A Phase 3 interventional study of Aspirin 81Mg Ec Tab and Clopidogrel in Dry Age-related Macular Degeneration, sponsored by Navamindradhiraj University. Recruiting at 1 site in Thailand. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-12-15.
Sponsored by Navamindradhiraj University · Phase 3, Interventional, and Prevention
The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen.
Participants will divided in to three groups.
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's planned enrollment of 174 is above the median of 51 across 985 interventional studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Navamindradhiraj University is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
In this study, antiplatelet drugs are medications that patients take to treat their underlying condition, such as aspirin 81 mg/day or clopidogrel 75 mg/day.
Drug: Aspirin 81Mg Ec Tab · Drug: Clopidogrel
Antiplatelet drugs are medications that patients take to treat their underlying condition, such as aspirin 81 mg/day or clopidogrel 75 mg/day combined with N-acetylcysteine 600 mg/day.
Drug: Aspirin 81Mg Ec Tab · Drug: Clopidogrel · Drug: N-acetylcysteine
Patient with no medication used.
Patients take aspirin 81 mg per day.
Patients take clopidogrel 75 mg per day.
Patients are given N-acetylcysteine 600 mg per day.
Also known as: NAC-long
Drusen volume analysis
To assess AMD progression in patient with large drusen, drusen volume was measured and analyzed in each patient group by OCT scan
Time frame: 1 year
Best-corrected visual acuity change
To evaluate Best-corrected visual acuity in each patient group by ETDRS chart
Time frame: 1 year
Rate of disease progression
To evaluate disease progression to geographic atrophy or neovascular AMD by OCT scan and fundus photo
Time frame: 1 year
Side effects of medications intake
To evaluate the safety of the medication used by questionnaire
Time frame: 1 year
Documents are hosted by the registry — open the source record to download them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Navamindradhiraj University